US20020136782A1 - Composition patent for solid-dosage form of weight loss product - Google Patents
Composition patent for solid-dosage form of weight loss product Download PDFInfo
- Publication number
- US20020136782A1 US20020136782A1 US09/761,622 US76162201A US2002136782A1 US 20020136782 A1 US20020136782 A1 US 20020136782A1 US 76162201 A US76162201 A US 76162201A US 2002136782 A1 US2002136782 A1 US 2002136782A1
- Authority
- US
- United States
- Prior art keywords
- composition
- extract
- matter
- chromium
- http
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000004580 weight loss Effects 0.000 title claims abstract description 17
- 239000007909 solid dosage form Substances 0.000 title description 3
- 239000013589 supplement Substances 0.000 claims abstract description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 34
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical class CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 22
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 20
- 229910052804 chromium Inorganic materials 0.000 claims description 20
- 239000011651 chromium Substances 0.000 claims description 20
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 17
- 229960001948 caffeine Drugs 0.000 claims description 17
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 11
- 241000208253 Gymnema sylvestre Species 0.000 claims description 10
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 10
- 229960002179 ephedrine Drugs 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- 241000218671 Ephedra Species 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 7
- 235000010205 Cola acuminata Nutrition 0.000 claims description 7
- 244000228088 Cola acuminata Species 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 7
- 229910052720 vanadium Inorganic materials 0.000 claims description 7
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 7
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052748 manganese Inorganic materials 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 6
- 230000000476 thermogenic effect Effects 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 240000008554 Aloysia triphylla Species 0.000 claims description 5
- 235000013668 Aloysia triphylla Nutrition 0.000 claims description 5
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 5
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 5
- 240000003538 Chamaemelum nobile Species 0.000 claims description 5
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 5
- 244000302512 Momordica charantia Species 0.000 claims description 5
- 235000009811 Momordica charantia Nutrition 0.000 claims description 5
- 229930013930 alkaloid Natural products 0.000 claims description 5
- 235000017803 cinnamon Nutrition 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 230000037406 food intake Effects 0.000 claims description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
- 229960000367 inositol Drugs 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 235000006109 methionine Nutrition 0.000 claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 5
- 240000002900 Arthrospira platensis Species 0.000 claims description 4
- 241000227647 Fucus vesiculosus Species 0.000 claims description 4
- 244000203593 Piper nigrum Species 0.000 claims description 4
- 235000008184 Piper nigrum Nutrition 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- RLSBGGURBSZJLQ-SCGRZTRASA-N (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid zinc Chemical compound [Zn].N[C@@H](CCCN=C(N)N)C(O)=O.N[C@@H](CCCN=C(N)N)C(O)=O RLSBGGURBSZJLQ-SCGRZTRASA-N 0.000 claims description 3
- 240000004160 Capsicum annuum Species 0.000 claims description 3
- 244000298479 Cichorium intybus Species 0.000 claims description 3
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 3
- 241000675108 Citrus tangerina Species 0.000 claims description 3
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 3
- 240000006927 Foeniculum vulgare Species 0.000 claims description 3
- 229930182816 L-glutamine Natural products 0.000 claims description 3
- 235000019510 Long pepper Nutrition 0.000 claims description 3
- 235000000556 Paullinia cupana Nutrition 0.000 claims description 3
- 240000003444 Paullinia cupana Species 0.000 claims description 3
- 240000003455 Piper longum Species 0.000 claims description 3
- 235000021407 appetite control Nutrition 0.000 claims description 3
- 235000013614 black pepper Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 229930183009 gymnemic acid Natural products 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000001133 paullinia cupana hbk gum Substances 0.000 claims description 3
- 239000001331 rosmarinus officinalis leaf Substances 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 2
- 235000002283 Capsicum annuum var aviculare Nutrition 0.000 claims description 2
- 235000013303 Capsicum annuum var. frutescens Nutrition 0.000 claims description 2
- 235000002284 Capsicum baccatum var baccatum Nutrition 0.000 claims description 2
- 235000002568 Capsicum frutescens Nutrition 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 239000004470 DL Methionine Substances 0.000 claims description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 241000212342 Sium Species 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229960004874 choline bitartrate Drugs 0.000 claims description 2
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 2
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 2
- 229940102465 ginger root Drugs 0.000 claims description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 230000003212 lipotrophic effect Effects 0.000 claims description 2
- 239000001771 mentha piperita Substances 0.000 claims description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 2
- 229940107147 siberian ginseng root Drugs 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000001841 zingiber officinale Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000000378 dietary effect Effects 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 55
- 229940125396 insulin Drugs 0.000 description 28
- 102000004877 Insulin Human genes 0.000 description 27
- 108090001061 Insulin Proteins 0.000 description 27
- 239000003925 fat Substances 0.000 description 24
- 235000019197 fats Nutrition 0.000 description 24
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 12
- 229960002442 glucosamine Drugs 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 235000008216 herbs Nutrition 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 230000029087 digestion Effects 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000002026 carminative effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 241000208251 Gymnema Species 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 241000593806 Phyllis Species 0.000 description 4
- 244000273928 Zingiber officinale Species 0.000 description 4
- 235000006886 Zingiber officinale Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 235000008397 ginger Nutrition 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000037323 metabolic rate Effects 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 235000015438 Cola nitida Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940060736 chromium polynicotinate Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 230000004132 lipogenesis Effects 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 235000016425 Arthrospira platensis Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 235000002567 Capsicum annuum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 231100000244 chromosomal damage Toxicity 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 2
- 235000002780 gingerol Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 229940040504 lipotropic agent Drugs 0.000 description 2
- 239000003912 lipotropic agent Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 229940082787 spirulina Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 235000021411 American diet Nutrition 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010056465 Food craving Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 101710093473 Gurmarin Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000009233 Morning Sickness Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 101100123436 Schizosaccharomyces pombe (strain 972 / ATCC 24843) hap3 gene Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 240000000143 Turnera diffusa Species 0.000 description 1
- 240000001519 Verbena officinalis Species 0.000 description 1
- 235000018718 Verbena officinalis Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011738 major mineral Substances 0.000 description 1
- 235000011963 major mineral Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000004952 turnera diffusa Nutrition 0.000 description 1
- 150000003682 vanadium compounds Chemical class 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
Definitions
- This invention relates to the evolving science that a new and unique combination of ma huang extract (ephedrine alkaloids), caffeine and glucosamine sulfate results in increased weight loss and energy.
- Ma huang is a central nervous system stimulant that has the ability to open up the adrenergic receptor sites found primarily in the heart and lungs, thereby increasing the metabolic rate and calorie expenditure. The net result is the release of fatty acids from stored fat cells and a quicker conversion of the fat into energy. When combined with a modest amount of caffeine the thermogenic effects can be improved as much as 20% 1 . Ma huang also acts as an appetite suppressant. 2
- the ephedrine/caffeine combination has lean body mass saving properties 6, 7 and abolishes the decline in HDL-cholesterol during active weight loss due to the beta-agonistic properties of ephedrine. 8 Due to increased central nervous system stimulation, the combination significantly prolongs exercise time to exhaustion and improves performance in runners. 9, 10
- Glucosamine in the form of glucosamine sulfate, another ingredient of this compound, also contributes to weight loss.
- the cellular concentration of adenosine triphosphate rises.
- Cells do not store extra energy in the form of extra adenosine triphosphate.
- high adenosine triphosphate concentrations inhibit glycolysis.
- glucose is instead converted into glycogen and fat.
- lipase enzymes hydrolyze triglycerides into glycerol and free fatty acids in a process called lipolysis (the breakdown of fat). These molecules (primarily the free fatty acids) serve as blood-borne energy carriers that can be used by the liver, skeletal muscles, and other organs for aerobic respiration. 11
- Glucose triggers a rise in insulin.
- Insulin acts to lower blood glucose levels, regulating those levels through several actions, including lipogenesis (conversion of carbohydrate and protein into fat). Fat cells can't be metabolized when insulin levels are normal. When you have high insulin levels, you block lipolysis and store fat. The body must initiate lipolysis to supply the cellular energy source ATP, which is necessary for muscle contraction (energy). When you reduce the level of insulin, you burn fat to provide energy. Glucosamine blocks the effect of insulin, burning up stored fat and resulting in weight loss. 13
- the glucosamine keeps the glucose from being stored as fat, providing a temporary and reversible hyperglycemic effect that allows the glucose to be used as energy instead by blunting the insulin-induced increase in muscle glycogen content.
- 17 In addition to the hyperglycemic effect of glucosamine, Japanese studies on dogs and ducks demonstrate that glucosamine causes glucagon release in addition to its effect to suppress insulin release as well as its direct inhibitory effect on glucose utilization in tissues. 18
- the invention discloses the formula sets that embody the invention of the supplement composition for increasing weight loss and energy levels.
- the combination of ephedrine and caffeine increases fat loss, maintains muscle mass, prevents the fall of HDL cholesterol during weight loss, increases insulin sensitivity, reduces lipogenesis and is safe.
- the new and useful formula is further enhanced.
- a representative formula for Solid-Dosage Form of Weight Loss Product is as follows, one tablet contains: Vitamin B 6 (as pyridoxine HCl) 3.4 mg Zinc (as zinc citrate and arginate) 2.5 mg Manganese (as manganese arginate) 1.0 mg Chromium (as chromium Chelavite TM 100.0 mcg dinocitinate glycinate) ⁇ Gymnema sylvestre leaf and Gymnema sylvestre 83.4 leaf extract (25% gymnemic acids) Vanadium 34.5 mg Glucosamine sulfate 100.0 mg Lecithin 50.0 mg Inositol 13.4 mg DL-methionine 10.0 mg Choline bitartrate 10.08 mg Peppermint leaf 12.6 mg Fennel seed 8.0 mg Bladderwrack kelp 5.0 mg L-glutamine 2.0 mg DL-phenylalanine 2.0 mg Rosemary leaf 2.0 mg L-Tyrosine 2.0 mg Bitter melon extract
- Vitamin B6 (pyridoxine) helps the body process the protein, fat and carbohydrates in our diet. It is required in the metabolization of carbohydrate, fats and proteins and has a primary role in the utilization of proteins and amino acids, converting them to carbohydrates or fats for storage or energy. Vitamin B 6 also helps the body resist stress. Vitamin B 6 activates the release of glucogen from the muscles and liver and is thus responsible for the production of biological energy. It works with other vitamins and minerals to supply the energy used in our muscles, and plays a role in cell growth. 19
- Zinc arginate is a more absorbable form of zinc.
- Zinc citrate is well tolerated by most individuals and contains citric acid, an antioxidant.
- citric acid an antioxidant.
- a positive correlation between zinc and leptin has been recently noted, and both are known as important mediators in appetite control.
- a recent study indicates that the amelioration of sucrose-induced obesity by zinc repletion may be partly attributable to the hyperleptinemia induced by the mineral. 20
- Zinc also helps red blood cells pick up carbon dioxide and drop it off in the lungs to be exhaled. This exchange helps maintain the chemical environment muscle cells need to contract and produce energy. 21 Zinc deficiency acts as a sustaining factor in abnormal eating behavior. It's known that zinc activates the areas of the brain that govern taste and smell, and without those the desire to eat is vastly diminished.
- Manganese is a mineral that is required to manufacture enzymes necessary for the metabolism of proteins and fats, including those involved in blood sugar control, thyroid function, and energy metabolism. 22
- Chromium contributes to the prevention of adult-onset diabetes. It has been shown to decrease sugar cravings and is considered an effective treatment against both hypoglycemia and diabetes by improving glucose tolerance, increasing cell sensitivity to insulin, and reducing circulating insulin levels. 23
- Chromium polynicotinate has been shown to possess greater biological activity and is safer than other chromium supplements. It potentiates the effects of insulin and helps overcome insulin resistance in overweight people. Chromium also seems to stimulate thermogenesis, the burning of fat, without any physical exertion. 25
- Chromium picolinate was found to cause significant chromosome damage at a non-toxic dose.
- chromium polynicotinate did not cause chromosome damage at equivalent doses. Consumers are urged to switch to a nontoxic form of chromium, such as niacin-bound chromium, also known as chromium polynicotinate.
- 26 A 1998 study demonstrated that 9 out of 10 American diets fall short in chromium. The chromium levels of more than 40,000 men and women were measured in this study. After comparing various age groups, the study found that chromium levels plummet with the passage of time. 27 According to Dr. Michelle Rubin from the University of Maryland, in addition to increasing as we age, chromium needs rise dramatically during exercise. 28
- Vanadium is needed for cellular metabolism and for thyroid function. Research at the Grand Forks Human Nutrition Research Center suggests that vanadium is an essential nutrient beneficial for thyroid hormone metabolism. 35 A study at the University of British Columbia found that vanadium compounds could correct defective signaling pathways and increase the cells' response to insulin, which would aid normal processing of sugar in patients with diabetes. 36 Vanadium can mimic insulin. In other words, in research done with cells, it has been able to replace insulin. 37 Vanadium has recently been observed to have several physiological insulin-like effects by a post-insulin receptor kinase mechanism, making it very likely to have a favorable effect on carbohydrate metabolism. 38
- lecithins possess a lipotropic action i.e., they correct or check abnormalities in lipid metabolism. They will, for example, prevent the fatty livers that generally result when depancreatized animals are maintained with insulin and fed diets high in carbohydrates.
- a lipotropic agent may be defined as one which is involved in the conversion of neutral fats to phospholipids, a form in which they are more readily transported in the bloodstream. Choline is perhaps the single most effective such agent and is a part of the normally functioning metabolic cycle of fat. The lack of normal ability to metabolize fat leads to a consistently higher than normal serum lipid level and a less rapid return of the serum lipid level to the previous level following ingestion of fat. It has been observed that the most common specific lipotropic agents (choline, inositol and methionine) are effective when administered singly but, in addition, appear to have a synergistic action when administered simultaneously. 39
- Inositol is required for proper formation of cell membranes and helps in transporting fats within the body.
- Methionine is one of the nine essential amino acids; its major role is to facilitate fat and protein metabolism. It supplies sulfur and other compounds required by the body for normal metabolism and growth. 41
- Peppermint is the first of the ingredients that are part of the Appetite Control Blend. Peppermint is used as a carminative, allowing gas pressure to escape the stomach. It aids digestion and is held to be helpful for many stomach problems, irritable bowel syndrome, nausea, morning sickness, diarrhea, constipation and flatulence. 42 Peppermint enhances digestion by increasing stomach acidity. It slightly anesthetizes mucous membranes and the gastrointestinal tract. 43
- Fennel seed promotes gastrointestinal motility and, in higher concentrations, acts as an antispasmodic.
- Bladderwrack kelp is one of the richest natural sources of approximately 30 trace elements and major minerals. It regulates the thyroid function and may be very helpful in reducing obesity where it is associated with thyroid trouble. Bladderwrack kelp is also a metabolic stimulant. 45
- bitter melon At least three constituents of bitter melon have been reported to have hypoglycemic (blood-lowering) actions. Multiple controlled clinical studies have confirmed the benefit of bitter melon for people with diabetes. 46 Evidence indicates it works by stimulating insulin release from the pancreas. 47 Bitter melon is also thought to stimulate digestive function. 48
- Rosemary leaf relaxes the stomach and stimulates circulation and digestion. 49 Rosemary can serve as a source of natural antioxidants. 50
- L-Glutamine is one of the most common and widely used amino acids in the body. It is a carbon and nitrogen donor and helps replenish glycogen, which restores energy. In fact, it is used as a source of energy and nucleotide synthesis for all rapidly dividing cells in the body. In the absence of glucose, the body will use glutamine for energy, thus preventing hypoglycemia without muscle loss. 51
- Phenylalanine is one of two amino acids that govern the release of an intestinal hormone called cholecystokinin, known as CKK. This hormone signals the brain to feel satisfied after eating. People given CCK stop eating and feel full sooner. L-phenylalanine has a nutritional value; D-phenylalanine has painkilling and depression alleviating properties. DL-phenylalanine is a 50/50 mixture of these two forms. Its activity is enhanced by the presence of Vitamin B 6 . 52
- tyrosine which is the precursor to the neurotransmitter dopamine.
- Dopamine controls desire in the brain. It also has anti-depressive qualities.
- Guarana seed extract (providing 40 mg of caffeine) is the first of the ingredients in the Thermogenic Herbal Concentrates group. Caffeine and the closely related alkaloids theobromine and theophylline make up the primary active agents in guarana. Caffeine 's effects are well known and include stimulating the central nervous system, increasing metabolic rate and having a mild diuretic effect. 55 The tannic acid in guarana is astringent and probably accounts for its use as a digestive tonic. It is also a stimulant. 56
- Black pepper stimulates the production of gastric juices (carminative), aids digestion, strengthens the stomach, and tones the spleen. 57 It has also been reported to have strong lipolytic activity that resides in the outer layer of the fruit. 58 It has also been reported to have antioxidant properties.
- Ginger is said to stimulate gastric juices and has carminative properties.
- Ginger contains gingerol, an oleoresin that accounts for the characteristic aroma of ginger and explains its therapeutic properties. Components of gingerol have recently been studied and found to possess beneficial properties for the treatment of poor digestion, heartburn, vomiting and motion sickness. 60
- Spirulina a type of algae, is a rich source of protein, vitamins, minerals and essential fatty acids. In one double-blind study of sixteen overweight individuals, ingestion of 2.8 grams of spirulina three times per day for four weeks resulted in a small but statistically significant weight loss. 62
- Cayenne causes the brain to secrete more endorphins. It is considered thermogenic and is rich in Vitamin C. 63 It is said that a poorly nourished pituitary gland is sometimes responsible for people being overweight; cayenne also aids the pituitary gland to release an ample supply of protein, which helps adjust hormone balance in the body. 64
- Kola nut diminishes sensations of hunger and fatigue. It also acts as an aid to digestion.
- the properties of kola are the same as caffeine, modified only by the astringents present. Fresh kola nuts have stimulant action apart from the caffeine content. The active ingredients work together to stimulate the central nervous system, act as an anti-depressive and relieve fatigue and hunger. 66
- Ginseng strengthens the adrenal and reproductive glands and is useful for lack of energy, due to a general stimulatory effect that raises the physical and mental capacity for work.
- 67, 68 Results of a study published in the American Journal of Clinical Medicine show that ginseng at appropriate doses improves learning, memory and physical capabilities.
- a Canadian study shows that ginseng saponins enhance exercise endurance by altering fuel homeostasis during prolonged exercise, presumably by increasing FFA utilization in preference over glucose for cellular energy demands. 69
- Lemon verbena is a febrifuge and sedative. It is used as a stomachic, antipyretic and antispasmodic in dyspepsia, indigestion and flatulence. 70 Lemon verbena also has anti-inflammatory activity. 71
- Cinnamon has compounds with insulin-potentiating activity, thus lowering the amount of insulin required for glucose metabolism.
- Cinnamon is used as a carminative, astringent, antiseptic and as a stimulant. It stops vomiting and relieves flatulence.
- Cinnamon also reportedly has strong lipolytic properties. 74
- Chamomile is an anti-inflammatory, as well as a traditional remedy for stress and anxiety, indigestion and insomnia. 75 Chamomile produces a brilliant blue oil containing the compound azulene that is thought to serve as a natural digestive aid. 76
- Tangerine peel is useful for digestive disorders. It promotes proper digestion and relieves nausea and gas. 77
- Licorice is an anti-inflammatory. Its sweet flavor masks other, medicinal flavors. 78 Licorice cleanses the colon, decreases muscular spasms and promotes adrenal gland function. 79
- Chicory is a tonic, laxative and diuretic. 80 It is used for dyspeptic disorders.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Supplement compositions designed to support weight loss and increase energy.
Description
- The prior art regarding this invention arises from distinct areas not heretofore combined to create new and useful formula sets or new and useful improvements thereof regarding a Solid-dosage Form of a Weight Loss Product.
- This invention relates to the evolving science that a new and unique combination of ma huang extract (ephedrine alkaloids), caffeine and glucosamine sulfate results in increased weight loss and energy.
- Ma huang is a central nervous system stimulant that has the ability to open up the adrenergic receptor sites found primarily in the heart and lungs, thereby increasing the metabolic rate and calorie expenditure. The net result is the release of fatty acids from stored fat cells and a quicker conversion of the fat into energy. When combined with a modest amount of caffeine the thermogenic effects can be improved as much as 20% 1. Ma huang also acts as an appetite suppressant.2
- A double-blind, placebo-controlled study published in Metabolism finds a thermogenic synergism between ephedrine and caffeine. 3 A second study published in the International Journal of Obesity Related Metabolic Disorders concludes that the ephedrine/caffeine combination is safe and effective in long-term treatment in improving and maintaining weight loss.4 A third study, published in the American Journal of Clinical Nutrition, concludes that results show that ephedrine and caffeine can promote weight loss through an increase in energy expenditure or, in some individuals, a combination of an increase in energy expenditure and a decrease in food intake.5
- In addition, the ephedrine/caffeine combination has lean body mass saving properties 6, 7 and abolishes the decline in HDL-cholesterol during active weight loss due to the beta-agonistic properties of ephedrine.8 Due to increased central nervous system stimulation, the combination significantly prolongs exercise time to exhaustion and improves performance in runners.9, 10
- Glucosamine, in the form of glucosamine sulfate, another ingredient of this compound, also contributes to weight loss. When food intake by the body occurs at a faster rate than energy consumption, the cellular concentration of adenosine triphosphate rises. Cells, however, do not store extra energy in the form of extra adenosine triphosphate. When cellular adenosine triphosphate concentrations rise because more energy (from food) is available than can be immediately used, high adenosine triphosphate concentrations inhibit glycolysis. Under conditions of high cellular adenosine triphosphate concentrations, when glycolysis is inhibited, glucose is instead converted into glycogen and fat.
- When fat stored in adipose tissue is going to be used as an energy source, lipase enzymes hydrolyze triglycerides into glycerol and free fatty acids in a process called lipolysis (the breakdown of fat). These molecules (primarily the free fatty acids) serve as blood-borne energy carriers that can be used by the liver, skeletal muscles, and other organs for aerobic respiration. 11
- The effect of insulin on lipogenesis, the formation of fatty acids in the body, is blocked by glucosamine, indicating that glucosamine plays a role as a messenger for this insulin effect. 12 Insulin is secreted when there is high sugar content; insulin secretion allows for fat storage. High insulin levels trigger the hypothalamus to send hunger signals, which sets off a craving for carbohydrates; this leads one to eat more, which leads to more insulin. Excess carbohydrates are converted into glucose, and then stored as fat.
- Glucose triggers a rise in insulin. Insulin acts to lower blood glucose levels, regulating those levels through several actions, including lipogenesis (conversion of carbohydrate and protein into fat). Fat cells can't be metabolized when insulin levels are normal. When you have high insulin levels, you block lipolysis and store fat. The body must initiate lipolysis to supply the cellular energy source ATP, which is necessary for muscle contraction (energy). When you reduce the level of insulin, you burn fat to provide energy. Glucosamine blocks the effect of insulin, burning up stored fat and resulting in weight loss. 13
- Scientists have yet to determine at what point in the metabolic pathway glucosamine acts to block insulin, but several studies have demonstrated this fact. A study at the Washington University School of Medicine concluded that direct administration of glucosamine can rapidly lower cellular ATP levels and affect insulin action in fat cells by independent mechanisms. 14 A University of Southern California study further explains that glucosamine induced complete and reversible insulin resistances15. A third study at the Albert Einstein College of Medicine adds that the etiology of peripheral insulin resistance may be distinct from the rapid and marked impairment in insulin signaling and that glucosamine on insulin-stimulated glucose metabolism is a different mechanism.16 Essentially, the glucosamine keeps the glucose from being stored as fat, providing a temporary and reversible hyperglycemic effect that allows the glucose to be used as energy instead by blunting the insulin-induced increase in muscle glycogen content.17 In addition to the hyperglycemic effect of glucosamine, Japanese studies on dogs and ducks demonstrate that glucosamine causes glucagon release in addition to its effect to suppress insulin release as well as its direct inhibitory effect on glucose utilization in tissues.18
- By increasing the metabolic rate and calorie expenditure with ma huang and caffeine while simultaneously encouraging the body to use stored fat for energy, in conjunction with the carefully blended composition of other ingredients, this new product provides a unique and successful method for losing weight and increasing energy.
- Curriculum Vitae
- Albert M. Fleischner, Ph.D., has a doctorate in Pharmaceutical Chemistry from Rutgers University and has had over thirty years experience in the pharmaceutical industry with firms such as Schering Corporation, Lehn & Fink Division of Sterling Drugs, Bradley Pharmaceutical Corporation, Amerchol Division of CPC and the Goen Group companies. He has a number of published papers and two previously granted patents and has several patents pending.
- The invention discloses the formula sets that embody the invention of the supplement composition for increasing weight loss and energy levels. The combination of ephedrine and caffeine increases fat loss, maintains muscle mass, prevents the fall of HDL cholesterol during weight loss, increases insulin sensitivity, reduces lipogenesis and is safe. With the addition of glucosamine sulfate, the new and useful formula is further enhanced.
- We now discuss in detail the most preferred version, variants or embodiments of the invention. First, a few words on terminology. The claim term “a” includes one and more than one. The claim term “label” is used as defined in the Federal Food Drug & Cosmetic Act and the regulations promulgated thereunder. We now turn to discussing in great detail the best (or “preferred”) versions (or “embodiments”) of the invention.
- A representative formula for Solid-Dosage Form of Weight Loss Product is as follows, one tablet contains:
Vitamin B6 (as pyridoxine HCl) 3.4 mg Zinc (as zinc citrate and arginate) 2.5 mg Manganese (as manganese arginate) 1.0 mg Chromium (as chromium Chelavite ™ 100.0 mcg dinocitinate glycinate)† Gymnema sylvestre leaf and Gymnema sylvestre 83.4 leaf extract (25% gymnemic acids) Vanadium 34.5 mg Glucosamine sulfate 100.0 mg Lecithin 50.0 mg Inositol 13.4 mg DL-methionine 10.0 mg Choline bitartrate 10.08 mg Peppermint leaf 12.6 mg Fennel seed 8.0 mg Bladderwrack kelp 5.0 mg L-glutamine 2.0 mg DL-phenylalanine 2.0 mg Rosemary leaf 2.0 mg L-Tyrosine 2.0 mg Bitter melon extract 0.5 mg Guarana seed extract (40 mg caffeine) 192.0 (20.0-50.0 mg caffeine) Ma huang extract (12 mg ephedrine alkaloids) 150.0 mg (5.0-28.0 mg (aerial parts) ephedrine alkaloids) Black pepper 13.7 mg Ginger root 15.1 mg Long pepper 13.7 mg Spirulina blue-green algae 3.0 mg Cayenne pepper 2.0 mg Kola nut 2.0 mg Siberian ginseng root 2.0 mg Cinnamon twig 1.7 mg Lemon verbena herb 1.7 mg Chamomile flower 1.4 mg Licorice root 0.7 mg Tangerine peel 0.7 mg Chicory root 0.3 mg Excipients: Dicalcium Phosphate, Microcrystalline Cellulose, a sufficient quantity Croscarmellose Sodium, Stearic Acid, Magne- of each to make a sium Stearate, Silica, Pharmaceutical Glaze suitable tablet - The scientific rationale for the formulation is as follows:
- Vitamin B6 (pyridoxine) helps the body process the protein, fat and carbohydrates in our diet. It is required in the metabolization of carbohydrate, fats and proteins and has a primary role in the utilization of proteins and amino acids, converting them to carbohydrates or fats for storage or energy. Vitamin B 6 also helps the body resist stress. Vitamin B6 activates the release of glucogen from the muscles and liver and is thus responsible for the production of biological energy. It works with other vitamins and minerals to supply the energy used in our muscles, and plays a role in cell growth.19
- Zinc arginate is a more absorbable form of zinc. Zinc citrate is well tolerated by most individuals and contains citric acid, an antioxidant. A positive correlation between zinc and leptin has been recently noted, and both are known as important mediators in appetite control. A recent study indicates that the amelioration of sucrose-induced obesity by zinc repletion may be partly attributable to the hyperleptinemia induced by the mineral. 20
- Zinc also helps red blood cells pick up carbon dioxide and drop it off in the lungs to be exhaled. This exchange helps maintain the chemical environment muscle cells need to contract and produce energy. 21 Zinc deficiency acts as a sustaining factor in abnormal eating behavior. It's known that zinc activates the areas of the brain that govern taste and smell, and without those the desire to eat is vastly diminished.
- Manganese is a mineral that is required to manufacture enzymes necessary for the metabolism of proteins and fats, including those involved in blood sugar control, thyroid function, and energy metabolism. 22
- A deficiency in chromium results in glucose intolerance. Chromium contributes to the prevention of adult-onset diabetes. It has been shown to decrease sugar cravings and is considered an effective treatment against both hypoglycemia and diabetes by improving glucose tolerance, increasing cell sensitivity to insulin, and reducing circulating insulin levels. 23
- Research also indicates chromium's role in lowering total cholesterol, LDL cholesterol, and serum triglyceride levels and improves the LDL-to-HDL cholesterol ratio, according to Dr. Jeoffry Gordon in San Diego, Calif. Subsequent research supports this and suggests a greater role for chromium in the treatment and prevention of high cholesterol and cardiovascular disease. There is speculation chromium positively affects lipid profiles by its ability to increase insulin efficiency, thereby reducing elevated lipid levels. 24
- Chromium polynicotinate has been shown to possess greater biological activity and is safer than other chromium supplements. It potentiates the effects of insulin and helps overcome insulin resistance in overweight people. Chromium also seems to stimulate thermogenesis, the burning of fat, without any physical exertion. 25
- Chromium picolinate was found to cause significant chromosome damage at a non-toxic dose. In contrast, chromium polynicotinate did not cause chromosome damage at equivalent doses. Consumers are urged to switch to a nontoxic form of chromium, such as niacin-bound chromium, also known as chromium polynicotinate. 26 A 1998 study demonstrated that 9 out of 10 American diets fall short in chromium. The chromium levels of more than 40,000 men and women were measured in this study. After comparing various age groups, the study found that chromium levels plummet with the passage of time.27 According to Dr. Michelle Rubin from the University of Maryland, in addition to increasing as we age, chromium needs rise dramatically during exercise.28
- The gradual hypoglycemic (blood sugar-lowering) action of gymnema leaves was first documented in the late 1920s. 29 Gymnema leaves raise insulin levels in healthy volunteers.30 This may be due to regeneration of the cells in the pancreas that secrete insulin.31 Animal research shows that gymnema can also improve uptake of glucose into cells and prevent adrenaline from stimulating the liver to produce glucose, thereby raising blood sugar levels.32 The leaves are also noted for lowering serum cholesterol and triglycerides. 33 Gurmarin, another constituent of the leaves, and gymnemic acid have been shown to block the ability to taste sweets in humans.34
- Vanadium is needed for cellular metabolism and for thyroid function. Research at the Grand Forks Human Nutrition Research Center suggests that vanadium is an essential nutrient beneficial for thyroid hormone metabolism. 35 A study at the University of British Columbia found that vanadium compounds could correct defective signaling pathways and increase the cells' response to insulin, which would aid normal processing of sugar in patients with diabetes.36 Vanadium can mimic insulin. In other words, in research done with cells, it has been able to replace insulin.37 Vanadium has recently been observed to have several physiological insulin-like effects by a post-insulin receptor kinase mechanism, making it very likely to have a favorable effect on carbohydrate metabolism.38
- The benefits of glucosamine have already been discussed in detail, above.
- There is evidence that lecithins possess a lipotropic action, i.e., they correct or check abnormalities in lipid metabolism. They will, for example, prevent the fatty livers that generally result when depancreatized animals are maintained with insulin and fed diets high in carbohydrates. A lipotropic agent may be defined as one which is involved in the conversion of neutral fats to phospholipids, a form in which they are more readily transported in the bloodstream. Choline is perhaps the single most effective such agent and is a part of the normally functioning metabolic cycle of fat. The lack of normal ability to metabolize fat leads to a consistently higher than normal serum lipid level and a less rapid return of the serum lipid level to the previous level following ingestion of fat. It has been observed that the most common specific lipotropic agents (choline, inositol and methionine) are effective when administered singly but, in addition, appear to have a synergistic action when administered simultaneously. 39
- Inositol is required for proper formation of cell membranes and helps in transporting fats within the body. 40 Methionine is one of the nine essential amino acids; its major role is to facilitate fat and protein metabolism. It supplies sulfur and other compounds required by the body for normal metabolism and growth.41
- Peppermint is the first of the ingredients that are part of the Appetite Control Blend. Peppermint is used as a carminative, allowing gas pressure to escape the stomach. It aids digestion and is held to be helpful for many stomach problems, irritable bowel syndrome, nausea, morning sickness, diarrhea, constipation and flatulence. 42 Peppermint enhances digestion by increasing stomach acidity. It slightly anesthetizes mucous membranes and the gastrointestinal tract.43
- Fennel seed promotes gastrointestinal motility and, in higher concentrations, acts as an antispasmodic. 44 Bladderwrack kelp is one of the richest natural sources of approximately 30 trace elements and major minerals. It regulates the thyroid function and may be very helpful in reducing obesity where it is associated with thyroid trouble. Bladderwrack kelp is also a metabolic stimulant.45
- At least three constituents of bitter melon have been reported to have hypoglycemic (blood-lowering) actions. Multiple controlled clinical studies have confirmed the benefit of bitter melon for people with diabetes. 46 Evidence indicates it works by stimulating insulin release from the pancreas.47 Bitter melon is also thought to stimulate digestive function.48
- Rosemary leaf relaxes the stomach and stimulates circulation and digestion. 49 Rosemary can serve as a source of natural antioxidants.50
- L-Glutamine is one of the most common and widely used amino acids in the body. It is a carbon and nitrogen donor and helps replenish glycogen, which restores energy. In fact, it is used as a source of energy and nucleotide synthesis for all rapidly dividing cells in the body. In the absence of glucose, the body will use glutamine for energy, thus preventing hypoglycemia without muscle loss. 51
- Phenylalanine is one of two amino acids that govern the release of an intestinal hormone called cholecystokinin, known as CKK. This hormone signals the brain to feel satisfied after eating. People given CCK stop eating and feel full sooner. L-phenylalanine has a nutritional value; D-phenylalanine has painkilling and depression alleviating properties. DL-phenylalanine is a 50/50 mixture of these two forms. Its activity is enhanced by the presence of Vitamin B 6.52
- The body uses phenylalanine to manufacture tyrosine, which is the precursor to the neurotransmitter dopamine. Dopamine controls desire in the brain. It also has anti-depressive qualities. 53 Tyrosine produces thyroxin, which plays an important role in controlling metabolic rate. It may also be used as a mild appetite suppressant. It was proven in research studies that tyrosine supplementation results in increased performance over a control group.54
- Guarana seed extract (providing 40 mg of caffeine) is the first of the ingredients in the Thermogenic Herbal Concentrates group. Caffeine and the closely related alkaloids theobromine and theophylline make up the primary active agents in guarana. Caffeine 's effects are well known and include stimulating the central nervous system, increasing metabolic rate and having a mild diuretic effect. 55 The tannic acid in guarana is astringent and probably accounts for its use as a digestive tonic. It is also a stimulant.56
- The benefits of ma huang extract and its ephedrine alkaloids have been discussed above.
- Black pepper stimulates the production of gastric juices (carminative), aids digestion, strengthens the stomach, and tones the spleen. 57 It has also been reported to have strong lipolytic activity that resides in the outer layer of the fruit.58 It has also been reported to have antioxidant properties.
- Ginger is said to stimulate gastric juices and has carminative properties. 59 Ginger contains gingerol, an oleoresin that accounts for the characteristic aroma of ginger and explains its therapeutic properties. Components of gingerol have recently been studied and found to possess beneficial properties for the treatment of poor digestion, heartburn, vomiting and motion sickness.60
- Long pepper is thermogenic, carminative, expectorant and aids digestion. 61 Spirulina, a type of algae, is a rich source of protein, vitamins, minerals and essential fatty acids. In one double-blind study of sixteen overweight individuals, ingestion of 2.8 grams of spirulina three times per day for four weeks resulted in a small but statistically significant weight loss.62
- Cayenne causes the brain to secrete more endorphins. It is considered thermogenic and is rich in Vitamin C. 63 It is said that a poorly nourished pituitary gland is sometimes responsible for people being overweight; cayenne also aids the pituitary gland to release an ample supply of protein, which helps adjust hormone balance in the body.64
- Kola nut diminishes sensations of hunger and fatigue. It also acts as an aid to digestion. 65 The properties of kola are the same as caffeine, modified only by the astringents present. Fresh kola nuts have stimulant action apart from the caffeine content. The active ingredients work together to stimulate the central nervous system, act as an anti-depressive and relieve fatigue and hunger.66
- Ginseng strengthens the adrenal and reproductive glands and is useful for lack of energy, due to a general stimulatory effect that raises the physical and mental capacity for work. 67, 68 Results of a study published in the American Journal of Clinical Medicine show that ginseng at appropriate doses improves learning, memory and physical capabilities. A Canadian study shows that ginseng saponins enhance exercise endurance by altering fuel homeostasis during prolonged exercise, presumably by increasing FFA utilization in preference over glucose for cellular energy demands.69
- Lemon verbena is a febrifuge and sedative. It is used as a stomachic, antipyretic and antispasmodic in dyspepsia, indigestion and flatulence. 70 Lemon verbena also has anti-inflammatory activity.71
- Cinnamon has compounds with insulin-potentiating activity, thus lowering the amount of insulin required for glucose metabolism. 72 Cinnamon is used as a carminative, astringent, antiseptic and as a stimulant. It stops vomiting and relieves flatulence.73 Cinnamon also reportedly has strong lipolytic properties.74
- Chamomile is an anti-inflammatory, as well as a traditional remedy for stress and anxiety, indigestion and insomnia. 75 Chamomile produces a brilliant blue oil containing the compound azulene that is thought to serve as a natural digestive aid.76
- Tangerine peel is useful for digestive disorders. It promotes proper digestion and relieves nausea and gas. 77
- Licorice is an anti-inflammatory. Its sweet flavor masks other, medicinal flavors. 78 Licorice cleanses the colon, decreases muscular spasms and promotes adrenal gland function.79
- Chicory is a tonic, laxative and diuretic. 80 It is used for dyspeptic disorders.
- Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The specific formulas are included as a preferred embodiment of the composition formula ranges, and not to further qualify the description. Claim references to specific components include the component itself, as well as concentrates, metabolites, constituents, extracts or combinations of said ingredients.
- 1 http://www.ephedra.net
- 2 Leung, A., Foster, S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics. 1996;2:228.
- 3 Metabolism 1991;March;40(3):323-9.
- 4 Int J Obes Relat Metab Disord 1993 December;17 Suppl 3:573-7;discussion 582.
- 5 Am J Clin Nutr 1998 July;68(1):42-51.
- 6 Int J Obes Relat Metab Disord 1993 February;17 Suppl 1:569-72.
- 7 Metabolism 1992 July;41(7):686-8.
- 8 Int J Obes Relat Metab Disord 1994 May;18(5):329-32.
- 9 Eur J Appl Physiol 1998 April;77(5):427-33.
- 10 Bell, D G, Jacobs, I. Aviat Space Environ Med 1999; 70:325-9.
- 11 Fox, Stuart I. Human Physiology, 5th ed., p. 112.
- 12 Biochem J 1990 March 15;266(3):909-16.
- 13 ibid.
- 14 J Biol Chem 1998 August 7;273(32):20658-68.
- 15 Am J Physiol Endocrinol Metab 2000 January;278(1):E103-12.
- 16 J Biol Chem 1999 October 29;274(44):31312-9.
- 17 Diabetes 1999 August;48(8):1562-71.
- 18 Endocrinol Jpn 1975 December;22(6):517-23.
- 19 http://health.excite.com/content/article/3187.10144 Excite Health with WebMD
- 20 Mann, Denise Zinc Deficiency Linked to Weight Loss Hormone Medical Tribune News Service 1998; June 29.
- 21 http://www.ars.usda.gov/is/pr/1999/990817.htm.
- 22 http://www.bodywise.com/prdoucts/ingredients/manganese.htm
- 23 http://www.vitaminsplus.com/library/minerals/chromium.asp
- 24 Ibid.
- 25 http://members.aol.com/gwag16/dietnutrition/whatis.htm
- 26 http://anndeweesallen.com/dal ra01.htm
- 27 Dolby, Victoria. Chromium at the Energy Crossroads. Better Nutrition Magazine, 1998;May
- 28 http://qualitycounts.com/fp/chromiumat.html
- 29 Mhasker K S, Caius J F. A study of Indian medicinal plants. II. Gymnema sylvestre R.Br. Indian J Med Res Memoirs 1930;16:2-75.
- 30 Shanmugasundaram K R, et al. Insulinotropic activity of G. sylvestre, R.Br. and Indian medicinal herb used in controlling diabetes mellitus. Pharmacol Res Commun 1981;13:475-86.
- 31 Shanmugasundaram E R, et al. Possible regeneration of the islets of Langerhans in streptozotocin diabetic rats given Gymnema sylvestre leaf extracts. J Ethnopharmacol 1990;30:265-79.
- 32 Gymnema sylvestre. Alt Med Rev 1999;4:46-7[review].
- 33 Bishayee A, Chatterjee M. Hypolipidemic and antiatherosclerotic effects of oral Gymnema sylvestre R.Br. leaf extract in albino rats fed on a high fat diet. Phytother Res b 1994;8:118 -20.
- 34 http://www.healthwell.com/healthnotes/Herb/Gymnema.cfm
- 35 http://www.gfhnrc.ars.usda.gov/News/nws9808a.htm
- 36 http://www.publicaffairs.ubc.ca/mr/mr98/mr-98- 100.html
- 37 http://www.diabetesnet.com/vanad.html
- 38 http://www.mdschoice.com/text/abstracts/vanadiab.htm Role of Essential Trace Elements in the Disturbance of Carbohydrate Metabolism
- 39 Textbook of Organic Medicinal and Pharmaceutical Chemistry Wilson C, Gisvold O-3rd ed. 1956. p.39.
- 40 http://www.mothernature.com/ency/Supp/inositol.asp
- 41 http://www.mothernature.com/ency/Supp/Methionine.asp
- 42 http://64.224.111.158/IMCAccess/ProfHerbs/Peppermintph.html
- 43 Balch, James F. Prescription for Nutritional Healing: A Practical A to Z Reference to Drug-Free Remedies Using Vitamins, Minerals, Herbs & Food Supplements James F. Balch, Phyllis A. Balch-2nd ed. 1977. p.75.
- 44 http://onhealth.webmd.com/alternative/resource/herbs/item,15995.asp
- 45 http://seasilver.threadnet.com/Preventorium/kelp.htm
- 46 http://www.healthwell.com/healthnotes/Herb/Bitter Melon.cfm
- 47 http://thp.sickbay.com/substance.asp?ID=21
- 48 http://www.healthwell.com/healthnotes/Herb/Bitter Melon.cfm
- 49 Balch, James F. Prescription for Nutritional Healing: A Practical A to Z Reference to Drug-Free Remedies Using Vitamins, Minerals, Herbs & Food Supplements James F. Balch, Phyllis A. Balch-2nd ed. 1977. p.76.
- 50 Tyler, V. E., Brady L.R. Pharmacognosy, 8th ed. p. 76.
- 51 http://www.naturalhealthconsult.com/Monographs/glutamine.html
- 52 http://www.smartbasic.com/glos.aminos/phenylalanine.glos.html
- 53 http://www.cockatoo.com/damiana/aminoacids.htm
- 54 http://www.lef.org/protocols/prtcls-txt/t-prtc189.html
- 55 Leung A Y, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics, 2d ed. New York: John Wiley & Sons, 1996, 293-4.
- 56 http://www.health-pages.com/gu/
- 57 http://www.imm.org.pl/bird/pepper.htm
- 58 Tyler, V. E., Brady L. R. Pharmacognosy, 8th ed. p. 416.
- 59 Ibid, p. 272.
- 60 http://www.hometownrx.com/Docs/Herbs/Ginger.html
- 61 http://www.healthseva.com/content/home remedies/herbs/indianlong.php3
- 62 http:/www.mothernature.com/ency/concern/Weight Loss.asp
- 63 http://www.herba-medica.com/remedies/capsicum.html
- 64 Ibid.
- 65 http://www.britannica.com/bcom/eb/article/3/0,5716,46993+1+45921,00.html?query=kola%20nut
- 66 http://www.nopal.com/kolanut.html
- 67 Balch, James F. Prescription for Nutritional Healing: A Practical A to Z Reference to Drug-Free Remedies Using Vitamins, Minerals, Herbs & Food Supplements James F. Balch, Phyllis A. Balch-2nd ed. 1977. p.71.
- 68 Petkov V D, Mosharrof A H, Effects of standardized ginseng extract on learning, memory and physical capabilities. Am J Chin Med 1987;15(1-2):19-29.
- 69 Wang L C, Lee T F, Effect of ginseng saponins on exercise performance in non-trained rats. Planta Med 1998 March;64(2):130-3.
- 70 http://www.hort.purdue.edu/newcrop/med-aro/factsheets/LEMON VERBENA.html
- 71 Deepak M, Handa S S Anti-inflammatory activity and chemical composition of extracts of verbena officinalis. Phytother Res 2000 September;14(6):463-5.
- 72 http:/ott.arsusda.gov/Inv/a395565.htm
- 73 www.botanical.com/botanical/mgmn/c/cinnam69.html
- 74 Tyler, V. E., Brady L. R. Pharmacognosy, 8th ed. p. 168
- 75 Balch, James F. Prescription for Nutritional Healing: A Practical A to Z Reference to Drug-Free Remedies Using Vitamins, Minerals, Herbs & Food Supplements James F. Balch, Phyllis A. Balch-2nd ed. 1977. p.67
- 76 http:www.lifehealthenergy.com/htdocs/TheMall/herbs/chamomile.htm.
- 77 Powerful and Unusual Herbs from the Amazon and China, the World Preservation Society, Inc. 1993, 1995.
- 78 Tyler, V. E., Brady L. R. Pharmacognosy, 8th ed. p. 348.
- 79 http://www.rain-tree.com/licorice.htm
- 80 http://www.botanical.com/botanical/mgmn/c/chicor61.html
Claims (4)
1. A composition of matter intended to support weight loss and increase energy,
(a) said composition of matter containing (i) Vitamin B6 and (ii) zinc, and (iii) (iv) manganese, and (v) chromium, and (vi) gymnema sylvestre leaf and extract, and (vii) vanadium, and (viii) glucosamine sulfate, and (ix) lipotropic blend, and (x) appetite control blend, and (xi) thermogenic herbal concentrates.
(b) said composition of matter intended for ingestion in capsule or tablet form; and
(c) said composition of matter not represented for use as a conventional food or as the sole item of a meal or diet; and
(d) said composition of matter labeled as a supplement for use in or by humans.
2. A composition of matter intended to support weight loss and increased energy.
3. (a) said combination of matter containing (i) ma huang extract and (ii) guarana, and (iii) glucosamine sulfate, and (iv) additional dietary substances which support the primary ingredients' activities.
(b) same
(c) same
(d) same
4. The dietary supplement of claim #3 wherein said ingredients are present in any combination thereof in the following approximate amounts:
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/761,622 US20020136782A1 (en) | 2001-01-18 | 2001-01-18 | Composition patent for solid-dosage form of weight loss product |
| US09/928,715 US6420350B1 (en) | 2001-01-18 | 2001-08-13 | Weight loss product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/761,622 US20020136782A1 (en) | 2001-01-18 | 2001-01-18 | Composition patent for solid-dosage form of weight loss product |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/928,715 Continuation-In-Part US6420350B1 (en) | 2001-01-18 | 2001-08-13 | Weight loss product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20020136782A1 true US20020136782A1 (en) | 2002-09-26 |
Family
ID=25062786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/761,622 Abandoned US20020136782A1 (en) | 2001-01-18 | 2001-01-18 | Composition patent for solid-dosage form of weight loss product |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US20020136782A1 (en) |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040071681A1 (en) * | 2002-10-10 | 2004-04-15 | Lydia Muller | Method and composition for reducing cravings for a craved substance |
| US20040077556A1 (en) * | 2002-04-22 | 2004-04-22 | Robert Chinery | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| US20040265398A1 (en) * | 2002-04-25 | 2004-12-30 | Fleischner Albert M. | Herbal composition for weight control |
| US20050053555A1 (en) * | 2003-07-14 | 2005-03-10 | Crave Busters, Llc. | Appetite control compositions and methods of use |
| US20050054584A1 (en) * | 2001-03-13 | 2005-03-10 | Erich Eigenbrodt | Use of sugar phosphates, sugar phosphate analog, amino acids, amino acid analogs for modulating transaminases and/or the association of p36/ malate dehydrogenase |
| WO2005007113A3 (en) * | 2003-07-14 | 2005-05-06 | Crave Busters Llc | Appetite control compositions and methods of use |
| US20050130935A1 (en) * | 2002-04-19 | 2005-06-16 | Weidner Morten S. | Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| WO2005023240A3 (en) * | 2003-09-04 | 2005-10-06 | Dana Flavin-Koenig | Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto |
| US20070042058A1 (en) * | 2005-08-17 | 2007-02-22 | Liliana George | Delivery System For Appetite Suppressant |
| US20070172510A1 (en) * | 2006-01-23 | 2007-07-26 | Melton Marc R | Energy drink |
| US20080038384A1 (en) * | 2006-08-11 | 2008-02-14 | Howard Sachs | Formulation to aid in management of Irritable Bowel Syndrome with urgency symptoms. |
| WO2009024175A1 (en) * | 2007-08-21 | 2009-02-26 | Atp Marketing & Promotion Ag | Herbal formulations for controlling blood glucose levels in patients with diabetes |
| WO2009006366A3 (en) * | 2007-07-03 | 2009-03-19 | Vincent James Entpr Llc | Weight loss composition |
| US20100135945A1 (en) * | 2008-12-02 | 2010-06-03 | Kreations By Kristin, Llc | Gymnema-containing lip balm compositions and associated methods |
| US20100151023A1 (en) * | 2006-09-01 | 2010-06-17 | Cathy Beggan | Time delayed release mechanism for energizing composition and method of use |
| US20100285179A1 (en) * | 2007-11-16 | 2010-11-11 | Bioclinical Development, Inc | Edible energy composition with low caffeine |
| US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| ITPD20110179A1 (en) * | 2011-05-27 | 2012-11-28 | Sanypet Spa | EDIBLE COMPOSITION FOR THE CONTROL OF DISGLICEMIA IN ANIMALS AND PRODUCT FOR THE FEEDING OF ANIMALS CONTAINING SUCH COMPOSITION |
| EP1707191B1 (en) * | 2005-03-31 | 2013-06-26 | BASF Beauty Care Solutions France SAS | Use of plant extracts to dye skin according to its phototype |
| US9049879B2 (en) | 2008-06-13 | 2015-06-09 | International Ip Holdings Llc | Edible energy composition |
| US20150257425A1 (en) * | 2014-03-14 | 2015-09-17 | New Chapter, Inc. | Supplemental Food |
| US9421217B2 (en) * | 2014-06-12 | 2016-08-23 | Four LLC | Sweet taste receptor antagonist compositions |
| CN106028837A (en) * | 2014-03-20 | 2016-10-12 | 雀巢产品技术援助有限公司 | Methods and compositions for using cinnamaldehyde and zinc for weight management |
| US20160331709A1 (en) * | 2015-05-13 | 2016-11-17 | Wow Llc??? | Balancing an Unbalanced Sympathetic Nervous System |
| US10881661B2 (en) | 2008-06-13 | 2021-01-05 | International Ip Holdings Llc | Edible energy composition |
| WO2021124244A1 (en) * | 2019-12-20 | 2021-06-24 | Idi Integratori Dietetici Italiani S.R.L. | Gastro-resistant microparticles comprising inositol and/or gymnema sylvestre extract, pharmaceutical and nutraceutical compositions thereof and uses thereof |
| WO2023007441A1 (en) * | 2021-07-30 | 2023-02-02 | Primavera Biosciences, Inc. | Treatment of sleep apnea |
-
2001
- 2001-01-18 US US09/761,622 patent/US20020136782A1/en not_active Abandoned
Cited By (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054584A1 (en) * | 2001-03-13 | 2005-03-10 | Erich Eigenbrodt | Use of sugar phosphates, sugar phosphate analog, amino acids, amino acid analogs for modulating transaminases and/or the association of p36/ malate dehydrogenase |
| US20050130935A1 (en) * | 2002-04-19 | 2005-06-16 | Weidner Morten S. | Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| US20040077556A1 (en) * | 2002-04-22 | 2004-04-22 | Robert Chinery | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| US20040265398A1 (en) * | 2002-04-25 | 2004-12-30 | Fleischner Albert M. | Herbal composition for weight control |
| US20040071681A1 (en) * | 2002-10-10 | 2004-04-15 | Lydia Muller | Method and composition for reducing cravings for a craved substance |
| US20060127452A1 (en) * | 2002-10-10 | 2006-06-15 | Lydia Muller | Method and composition for reducing cravings for a craved substance |
| WO2005007113A3 (en) * | 2003-07-14 | 2005-05-06 | Crave Busters Llc | Appetite control compositions and methods of use |
| US20050053555A1 (en) * | 2003-07-14 | 2005-03-10 | Crave Busters, Llc. | Appetite control compositions and methods of use |
| WO2005023240A3 (en) * | 2003-09-04 | 2005-10-06 | Dana Flavin-Koenig | Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto |
| US20070031510A1 (en) * | 2003-09-04 | 2007-02-08 | Dana Flavin-Koenig | Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto |
| US8268363B2 (en) | 2003-09-04 | 2012-09-18 | Dana Flavin-Koenig | Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto |
| WO2005039493A3 (en) * | 2003-10-24 | 2005-10-13 | Trimspa Corp | Herbal composition for weight control |
| US20060105068A1 (en) * | 2003-10-24 | 2006-05-18 | Fleischner Albert M | Dietary supplement formulations containing Hoodia gordonii |
| EP1707191B1 (en) * | 2005-03-31 | 2013-06-26 | BASF Beauty Care Solutions France SAS | Use of plant extracts to dye skin according to its phototype |
| US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8263667B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8197854B2 (en) | 2005-08-04 | 2012-06-12 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US20070042058A1 (en) * | 2005-08-17 | 2007-02-22 | Liliana George | Delivery System For Appetite Suppressant |
| US20070172510A1 (en) * | 2006-01-23 | 2007-07-26 | Melton Marc R | Energy drink |
| US20080038384A1 (en) * | 2006-08-11 | 2008-02-14 | Howard Sachs | Formulation to aid in management of Irritable Bowel Syndrome with urgency symptoms. |
| US8968799B2 (en) * | 2006-09-01 | 2015-03-03 | Rise-N-Shine L.L.C. | Time delayed release mechanism for energizing composition and method of use |
| US20100151023A1 (en) * | 2006-09-01 | 2010-06-17 | Cathy Beggan | Time delayed release mechanism for energizing composition and method of use |
| WO2009006366A3 (en) * | 2007-07-03 | 2009-03-19 | Vincent James Entpr Llc | Weight loss composition |
| US20090214680A1 (en) * | 2007-07-03 | 2009-08-27 | Vincent Giuliano | Weight Loss Composition |
| US7989007B2 (en) | 2007-07-03 | 2011-08-02 | Vincent James Enterprises, Llc | Weight loss composition |
| US20110217396A1 (en) * | 2007-08-21 | 2011-09-08 | Atp Marketing & Promotion Ag | Herbal Formulations for Controlling Blood Glucose Levels in Patients with Diabetes |
| JP2010536806A (en) * | 2007-08-21 | 2010-12-02 | エイティピー・マーケティング・アンド・プロモーション・アクチェンゲゼルシャフト | Herbal preparations for controlling blood glucose levels in diabetic patients |
| WO2009024175A1 (en) * | 2007-08-21 | 2009-02-26 | Atp Marketing & Promotion Ag | Herbal formulations for controlling blood glucose levels in patients with diabetes |
| US11540551B2 (en) | 2007-11-16 | 2023-01-03 | International Ip Holdings Llc | Edible edible composition with low caffeine |
| EP2214521A4 (en) * | 2007-11-16 | 2014-05-14 | Internat Ip Holdings Llc | COMBINABLE ENERGY COMPOSITION WITH LOW CAFFEINE CONTENT |
| US20100285179A1 (en) * | 2007-11-16 | 2010-11-11 | Bioclinical Development, Inc | Edible energy composition with low caffeine |
| US9526268B2 (en) | 2007-11-16 | 2016-12-27 | International Ip Holdings Llc | Edible energy composition with low caffeine |
| US8993033B2 (en) | 2007-11-16 | 2015-03-31 | International Ip Holdings, Llc | Edible energy composition with low caffeine |
| US10721955B2 (en) | 2007-11-16 | 2020-07-28 | International Ip Holdings Llc | Edible energy composition with low caffeine |
| US10201179B2 (en) | 2007-11-16 | 2019-02-12 | International Ip Holdings Llc | Edible energy composition with low caffeine |
| US9049879B2 (en) | 2008-06-13 | 2015-06-09 | International Ip Holdings Llc | Edible energy composition |
| US9480697B2 (en) | 2008-06-13 | 2016-11-01 | International Ip Holdings Llc | Edible energy composition |
| US10881661B2 (en) | 2008-06-13 | 2021-01-05 | International Ip Holdings Llc | Edible energy composition |
| US20100135945A1 (en) * | 2008-12-02 | 2010-06-03 | Kreations By Kristin, Llc | Gymnema-containing lip balm compositions and associated methods |
| ITPD20110179A1 (en) * | 2011-05-27 | 2012-11-28 | Sanypet Spa | EDIBLE COMPOSITION FOR THE CONTROL OF DISGLICEMIA IN ANIMALS AND PRODUCT FOR THE FEEDING OF ANIMALS CONTAINING SUCH COMPOSITION |
| US9788560B2 (en) * | 2014-03-14 | 2017-10-17 | The Procter & Gamble Company | Supplemental food |
| US20150257425A1 (en) * | 2014-03-14 | 2015-09-17 | New Chapter, Inc. | Supplemental Food |
| CN106028837A (en) * | 2014-03-20 | 2016-10-12 | 雀巢产品技术援助有限公司 | Methods and compositions for using cinnamaldehyde and zinc for weight management |
| US9421217B2 (en) * | 2014-06-12 | 2016-08-23 | Four LLC | Sweet taste receptor antagonist compositions |
| JP2017519046A (en) * | 2014-06-12 | 2017-07-13 | フォー・エル・エル・シー | Sweetness receptor antagonist composition |
| US20170143793A1 (en) * | 2014-06-12 | 2017-05-25 | Four LLC | Sweet taste receptor antagonist compositions |
| US9585905B2 (en) | 2014-06-12 | 2017-03-07 | Four LLC | Sweet taste receptor antagonist compositions |
| US20160331709A1 (en) * | 2015-05-13 | 2016-11-17 | Wow Llc??? | Balancing an Unbalanced Sympathetic Nervous System |
| WO2021124244A1 (en) * | 2019-12-20 | 2021-06-24 | Idi Integratori Dietetici Italiani S.R.L. | Gastro-resistant microparticles comprising inositol and/or gymnema sylvestre extract, pharmaceutical and nutraceutical compositions thereof and uses thereof |
| WO2023007441A1 (en) * | 2021-07-30 | 2023-02-02 | Primavera Biosciences, Inc. | Treatment of sleep apnea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020136782A1 (en) | Composition patent for solid-dosage form of weight loss product | |
| US7989007B2 (en) | Weight loss composition | |
| KR100645385B1 (en) | Obesity Inhibitory Composition | |
| US20210220422A1 (en) | Dietary supplement compositions and methods | |
| Zovko Koncic et al. | New insights into dietary supplements used in sport: active substances, pharmacological and side effects | |
| US7335651B2 (en) | Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation | |
| US7955624B2 (en) | Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis | |
| US20060204599A1 (en) | Dietary supplement and method of using same | |
| CN101132697A (en) | Compositions for weight loss and methods for weight loss | |
| US20160184375A1 (en) | Sea Buckthorn Compositions and Associated Methods | |
| US20040265398A1 (en) | Herbal composition for weight control | |
| Talbott et al. | The health professional's guide to dietary supplements | |
| US20090214684A1 (en) | Method for reducing body weight and improving control of body lipids | |
| US20200022949A1 (en) | Composition and method for the alleviation of effects of alcohol consumption | |
| JP2005325025A (en) | Diabetes-preventing/treating composition | |
| US20070178176A1 (en) | Composition and method for promoting weight loss | |
| KR100455222B1 (en) | A diet ginseng products and the preparing method thereof | |
| US20100015259A1 (en) | Composition and method for improving human concentration, memory and other cognitive brain | |
| US20030039708A1 (en) | Non-ma huang herb weight loss product | |
| US6932987B1 (en) | Chemical composition and method for enhancing metabolism | |
| US20170056463A1 (en) | Compositions and methods for treating diabetes | |
| US20020197338A1 (en) | Botanical composition and methods for the treatment or prevention of obesity | |
| US20120231098A1 (en) | Weight loss composition | |
| US20190160138A1 (en) | Dietary supplement for gluten reaction | |
| KR102180363B1 (en) | An anti-impotence formula comprising black sesame and yeast hydrolysate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: GOEN GROUP, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FLEISCHNER, ALBERT M.;REEL/FRAME:012934/0943 Effective date: 20020225 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |